Table 2 Summary of druggability and clinical development activity for multiple myeloma associated with causal associations on Mendelian randomization analysis

NAMPT

In development

DAPORINAD^b

(CHEMBL566757)

Small molecule

Inhibitor

Phase I/II trials: cutaneous T-cell Lymphoma, melanoma, B-cell chronic lymphocytic leukemia

In development

TEGLARINAD^b

(CHEMBL1181731)

Small molecule

Inhibitor

Phase I trial: lymphoma

In development

ATG-019^c

Small molecule

Inhibitor

Phase I trial: non-Hodgkin's lymphoma (NCT04281420)

In development

KPT-9274^c

Small molecule

Inhibitor

Phase I trial: non-Hodgkin's lymphoma, acute myeloid leukemia (NCT02702492)

TIE1

In development

CP-459632^b

(CHEMBL3545300)

Small molecule

Inhibitor

-

FSTL1

Druggable^a

-

Antibody^a

-

-

CBR1

Druggable^a

-

Small molecule^a

-

-

GZMB

Druggable^a

-

Small molecule^a

-

-

PDE4D

In development

ZATOLMILAST^b

(CHEMBL4541964)

Small molecule

Inhibitor

Phase II trials: Alzheimer’s disease, fragile X syndrome, depression

GPC1

Druggable^a

-

Antibody^a

-

-

C1QC

Druggable^a

-

Antibody^a

-

-

FCGR3B

In development

IMGATUZUMAB^b

(CHEMBL2109389)

Antibody

Cross-linking agent

Phase I/II trials: colorectal neoplasms, head and neck neoplasms, non-small-cell lung

NCF2

Not currently listed as druggable

-

-

-

-

PTPN4

Not currently listed as druggable

-

-

-

-

SOCS3

Not currently listed as druggable

-

-

-

-

PAFAH1B2

Not currently listed as druggable

-

-

-

-